Retatrutide

About the substance

Retatrutide is an investigational peptide described as a triple receptor agonist. It targets GIP, GLP-1 and glucagon receptors. “Triple” refers to the three receptor targets of one molecule; it does not mean that the pen contains three separate peptide products.

How it works

These hormone pathways are involved in metabolic regulation. Studying them together helps examine how multiple signals influence body weight and glucose control. Receptor activity describes a biological mechanism, not a guaranteed outcome for a particular person or product.

What studies have examined

A randomised phase II trial in adults with obesity reported body-weight reductions with the trial formulation over 48 weeks. Gastrointestinal adverse events were common, and changes in heart rate were also observed. Both benefits and adverse effects belong in an account of the findings.

How to interpret the findings

The cited trial used controlled study material and medical follow-up. Its results do not verify the identity, purity, safety or clinical performance of this independently supplied pen. It should not be presented as equivalent to the study medicine or as an approved weight-management treatment.

Product specifications

• Format: Ready-mixed peptide pen
• Stated total quantity: 10 mg / 20 mg

The available 10 mg and 20 mg options indicate the total quantity per pen. They are product sizes, not recommended individual doses or treatment courses. Select the variant when comparing product content and price.

Documentation and handling

For details about identity, content and the available certificate, contact info@nordicpept.com and specify the product and batch. Follow the storage and handling instructions supplied with the actual product. A publication about an ingredient is not a certificate for a finished pen.

Selected studies

• Jastreboff et al., 2023